NCT01767467View on ClinicalTrials.gov

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

PHASE3CompletedINTERVENTIONAL
Enrollment

568

Participants

Timeline

Start Date

March 1, 2013

Primary Completion Date

January 7, 2016

Study Completion Date

January 6, 2017

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

Herpes zoster vaccine (GSK 1437173A)

2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.

DRUG

Placebo

2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.

Trial Locations (86)

112

GSK Investigational Site, Taipei

333

GSK Investigational Site, Taoyuan Hsien

404

GSK Investigational Site, Taichung

833

GSK Investigational Site, Kaohsiung City

1000

GSK Investigational Site, Brussels

1090

GSK Investigational Site, Jette

1200

GSK Investigational Site, Brussels

2010

GSK Investigational Site, Darlinghurst

2060

GSK Investigational Site, Antwerp

3000

GSK Investigational Site, Leuven

3058

GSK Investigational Site, Coburg

3240

GSK Investigational Site, Hamilton

3500

GSK Investigational Site, Hasselt

3690

GSK Investigational Site, Wodonga

7000

GSK Investigational Site, Hobart

8000

GSK Investigational Site, Bruges

8011

GSK Investigational Site, Christchurch

24019

GSK Investigational Site, Périgueux

27514

GSK Investigational Site, Chapel Hill

28009

GSK Investigational Site, Madrid

28033

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28050

GSK Investigational Site, Madrid

28100

GSK Investigational Site, Novara

28222

GSK Investigational Site, Majadahonda (Madrid)

28223

GSK Investigational Site, Pozuelo de Alarcón/Madrid

28933

GSK Investigational Site, Móstoles

33100

GSK Investigational Site, Udine

33520

GSK Investigational Site, Tampere

33604

GSK Investigational Site, Pessac

34295

GSK Investigational Site, Montpellier

34452

GSK Investigational Site, Inverness

39008

GSK Investigational Site, Santander

44093

GSK Investigational Site, Nantes

46514

GSK Investigational Site, Elkhart

47014

GSK Investigational Site, Meldola (FC)

54449

GSK Investigational Site, Marshfield

55455

GSK Investigational Site, Minneapolis

60637

GSK Investigational Site, Chicago

68070

GSK Investigational Site, Mulhouse

76038

GSK Investigational Site, Rouen

98108

GSK Investigational Site, Seattle

169608

GSK Investigational Site, Singapore

185019

GSK Investigational Site, Petrozavodsk

191024

GSK Investigational Site, St'Petersburg

197758

GSK Investigational Site, Saint Petersburg

603126

GSK Investigational Site, Nizhny Novgorod

620102

GSK Investigational Site, Yekaterinburg

02115

GSK Investigational Site, Boston

E2L 4L2

GSK Investigational Site, Saint John

B3K 6R8

GSK Investigational Site, Halifax

L1G 2B9

GSK Investigational Site, Oshawa

M4C 3E7

GSK Investigational Site, Toronto

128 08

GSK Investigational Site, Prague

00029

GSK Investigational Site, Helsinki

Unknown

GSK Investigational Site, Hong Kong

GSK Investigational Site, Lahore

GSK Investigational Site, Multan

GSK Investigational Site, Panama City

41-500

GSK Investigational Site, Chorzów

45-372

GSK Investigational Site, Opole

76-200

GSK Investigational Site, Słupsk

197 089

GSK Investigational Site, Saint Petersburg

614-735

GSK Investigational Site, Busan

700-721

GSK Investigational Site, Daegu

405-760

GSK Investigational Site, Incheon

519-809

GSK Investigational Site, Jellanamdo

561-712

GSK Investigational Site, Jeonju

410-769

GSK Investigational Site, Kyunggi-do

110-744

GSK Investigational Site, Seoul

135-710

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

08035

GSK Investigational Site, Barcelona

SE-631 88

GSK Investigational Site, Eskilstuna

SE-371 41

GSK Investigational Site, Karlskrona

SE-205 02

GSK Investigational Site, Malmo

SE-751 85

GSK Investigational Site, Uppsala

06500

GSK Investigational Site, Ankara

06590

GSK Investigational Site, Ankara

BR6 8ND

GSK Investigational Site, Orpington

ML6 0JS

GSK Investigational Site, Airdrie

SN3 6BB

GSK Investigational Site, Swindon

BH7 7DW

GSK Investigational Site, Bournemouth

OX3 7LE

GSK Investigational Site, Headington, Oxford

SE13 6LH

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01767467 - Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers | Biotech Hunter | Biotech Hunter